MX2013002579A - Compuesto de quinoxalina. - Google Patents

Compuesto de quinoxalina.

Info

Publication number
MX2013002579A
MX2013002579A MX2013002579A MX2013002579A MX2013002579A MX 2013002579 A MX2013002579 A MX 2013002579A MX 2013002579 A MX2013002579 A MX 2013002579A MX 2013002579 A MX2013002579 A MX 2013002579A MX 2013002579 A MX2013002579 A MX 2013002579A
Authority
MX
Mexico
Prior art keywords
disorders
compound
effect
bladder
therapeutic
Prior art date
Application number
MX2013002579A
Other languages
English (en)
Inventor
Hiroyuki Kaizawa
Ryushi Seo
Satoshi Yamamoto
Hirofumi Yamamoto
Mari Sugita
Kazunori Kamijo
Kazuyuki Tsuchiya
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2013002579A publication Critical patent/MX2013002579A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un compuesto que tiene una actividad inhibitoria de PDE9 y es útil como un ingrediente activo para un agente para tratar y/o prevenir disfunción de almacenaje, disfunción de evacuación, y enfermedades uretrales/de vejiga, y similares. Los presentes inventores han investigado un compuesto que tiene una acción inhibitoria de PDE9 y es útil como un ingrediente activo para un agente para tratar y/o prevenir disfunción de almacenaje, disfunción de evacuación, y enfermedades uretrales/de vejiga, y similares, y de esta manera, han encontrado que un compuesto de imidazoquinoxalina o compuesto de triazoloquinoxalina tiene una acción inhibitoria de PDE9, completando de este modo la presente invención. El compuesto de imidazoquinoxalina o el compuesto de triazoloquinoxalina de la presente invención tiene una acción inhibitoria de PDE9 y se puede usar como un agente para prevenir y/o tratar disfunción de almacenaje, disfunción de evacuación, y enfermedades uretrales/de vejiga y similares.
MX2013002579A 2010-09-07 2011-09-06 Compuesto de quinoxalina. MX2013002579A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010200402 2010-09-07
PCT/JP2011/070287 WO2012033101A1 (ja) 2010-09-07 2011-09-06 キノキサリン化合物

Publications (1)

Publication Number Publication Date
MX2013002579A true MX2013002579A (es) 2013-04-29

Family

ID=45810699

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002579A MX2013002579A (es) 2010-09-07 2011-09-06 Compuesto de quinoxalina.

Country Status (16)

Country Link
US (1) US8901126B2 (es)
EP (1) EP2615096B1 (es)
JP (1) JP5822080B2 (es)
KR (1) KR20130097178A (es)
CN (1) CN103097393B (es)
AU (1) AU2011299936A1 (es)
BR (1) BR112013005439A2 (es)
CA (1) CA2810659A1 (es)
EA (1) EA201390354A1 (es)
ES (1) ES2747423T3 (es)
MX (1) MX2013002579A (es)
PL (1) PL2615096T3 (es)
PT (1) PT2615096T (es)
TW (1) TW201300390A (es)
WO (1) WO2012033101A1 (es)
ZA (1) ZA201301673B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
WO2017046606A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
JOP20170164A1 (ar) 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
AR112457A1 (es) 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
TW201920188A (zh) * 2017-08-10 2019-06-01 美商美國禮來大藥廠 [1,2,4]三唑衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
WO1993012113A1 (en) 1991-12-17 1993-06-24 The Upjohn Company 3-SUBSTITUTED IMIDAZO (1,5-a) AND IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY
JPH07503970A (ja) 1992-02-19 1995-04-27 ジ・アップジョン・カンパニー ＣＮＳ活性を有する３−置換イミダゾ（１，５−ａ）−キノキサリン類およびキナゾリン類
DK31093D0 (es) 1993-03-19 1993-03-19 Novo Nordisk As
US6001832A (en) 1994-09-16 1999-12-14 Novo Nordiskals [1,2,4]triazolo[4,3-a]quinoxalinone derivatives, their preparation and use
CA2200056A1 (en) 1994-09-16 1996-03-21 Novo Nordisk A/S [1,2,4]triazolo[4,3-a]quinoxalinone derivatives, their preparation and use
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
CA2520251A1 (en) 2003-03-27 2004-10-07 Pfizer Products Inc. Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines
EP1908765B1 (en) 2005-06-14 2014-10-22 ASKA Pharmaceutical Co., Ltd. Thienopyrimidine derivative
JP5193866B2 (ja) 2006-08-08 2013-05-08 あすか製薬株式会社 キナゾリン誘導体
EP2489667B1 (en) * 2006-12-13 2015-04-15 ASKA Pharmaceutical Co., Ltd. Quinoxaline derivative
KR20090097918A (ko) 2006-12-13 2009-09-16 아스카 세이야쿠 가부시키가이샤 요로계 질환의 처치제
MX2011002340A (es) 2008-09-08 2011-04-04 Boehringer Ingelheim Int Pirazolopirimidinas y su uso para el tratamiento de trastornos del snc.
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
JP5609861B2 (ja) * 2009-03-05 2014-10-22 アステラス製薬株式会社 キノキサリン化合物

Also Published As

Publication number Publication date
TW201300390A (zh) 2013-01-01
JP5822080B2 (ja) 2015-11-24
US8901126B2 (en) 2014-12-02
US20130296329A1 (en) 2013-11-07
EP2615096A4 (en) 2014-03-05
PT2615096T (pt) 2019-10-15
CN103097393B (zh) 2015-09-16
KR20130097178A (ko) 2013-09-02
JPWO2012033101A1 (ja) 2014-01-20
CA2810659A1 (en) 2012-03-15
WO2012033101A1 (ja) 2012-03-15
AU2011299936A1 (en) 2013-03-28
EP2615096A1 (en) 2013-07-17
ZA201301673B (en) 2014-05-28
EA201390354A1 (ru) 2013-08-30
ES2747423T3 (es) 2020-03-10
CN103097393A (zh) 2013-05-08
BR112013005439A2 (pt) 2017-09-19
PL2615096T3 (pl) 2019-12-31
EP2615096B1 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PT2210588E (pt) Composição expansível, essencialmente isenta de ingredientes farmaceuticamente activos para o tratamento da pele humana
ZA201202384B (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
MX2013002579A (es) Compuesto de quinoxalina.
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
IN2012DN02081A (es)
MX2014010589A (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
SG170024A1 (en) Imidazole-based compounds, compositions comprising them and methods of their use
EA020330B3 (ru) Хиназолиновые соединения
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
MX2011009033A (es) Inhibidores triciclicos de cinasa pirazolopiridina.
EP2638910A4 (en) COMPOSITION WITH BENPROPERINE DERIVATIVES AS ACTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF ANGIOGENIC CONDITIONS
WO2012047525A3 (en) Folate conjugates for treating inflammation of the eye
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2014000066A (es) Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.
CA2863809A1 (en) Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
WO2012021800A3 (en) Caspase inhibitors as therapeutics for neural and organ injury and imaging
WO2009124103A3 (en) Combination therapies comprising par1 antagonists with par4 antagonists
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth

Legal Events

Date Code Title Description
FG Grant or registration